findmyKOL
Clinical trialNCT00100243CompletedPhase 2Interventional

Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

SponsorPRAECIS Pharmaceuticals Inc.Enrollment22Prostate Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled. Enrollment will be monitored to ensure that not all subjects are enrolled based on rising prostate specific antigen (PSA) criterion only. Subjects will be treated with abarelix (Plenaxis) 100 mg intramuscularly (IM) every 2 weeks for 12 weeks (total dose of 600 mg).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • San Diego Center for Urology

    La Mesa, California, United States

  • Southwest Florida Urological Associates

    Fort Myers, Florida, United States

  • Panama City Urological Center

    Panama City, Florida, United States

  • Columbus Urology Research, Llc

    Columbus, Ohio, United States

  • Oregon Health & Science University

    Portland, Oregon, United States

  • Urological Associates of Lancaster

    Lancaster, Pennsylvania, United States

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Plenaxis
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 May 2004
Primary completion
—
Completion
30 Sept 2005
Last update posted
19 Sept 2006
Registered enrollment
22
Registry id
NCT00100243
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.